These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33730613)

  • 1. Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability.
    Oliva A; Llabrés M
    J Pharm Biomed Anal; 2021 May; 198():114017. PubMed ID: 33730613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some thoughts on the QR method for analytical similarity evaluation.
    Son S; Oh M; Choo M; Chow SC; Lee SJ
    J Biopharm Stat; 2020 May; 30(3):521-536. PubMed ID: 32089068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
    Yang H; Novick S; Burdick RK
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the establishment of equivalence acceptance criterion in analytical similarity assessment.
    Wang T; Chow SC
    J Biopharm Stat; 2017; 27(2):206-212. PubMed ID: 28051920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical considerations regarding correlated lots in analytical biosimilar equivalence test.
    Shen M; Wang T; Tsong Y
    J Biopharm Stat; 2017; 27(2):213-219. PubMed ID: 27906604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Bootstrapping Test for Analytical Biosimilarity.
    Zahel T
    AAPS J; 2022 Oct; 24(6):112. PubMed ID: 36271265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical Similarity Assessment in Biosimilar Studies.
    Chow SC; Song F; Bai H
    AAPS J; 2016 May; 18(3):670-7. PubMed ID: 26873509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of statistical methods for analytical similarity assessment.
    Tsong Y; Dong X; Shen M
    J Biopharm Stat; 2017; 27(2):197-205. PubMed ID: 27977326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On sample size requirement for analytical similarity assessment.
    Zhao Y; Chang YW; Chow SC
    J Biopharm Stat; 2018; 28(6):1143-1159. PubMed ID: 29513612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
    MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment.
    Oliva A; Llabrés M
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34205892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars.
    Vandekerckhove K; Seidl A; Gutka H; Kumar M; Gratzl G; Keire D; Coffey T; Kuehne H
    AAPS J; 2018 May; 20(4):68. PubMed ID: 29748754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous confidence interval methods for analytical similarity assessment.
    Zheng J; Yin D; Yuan M; Chow SC
    J Biopharm Stat; 2019; 29(5):920-940. PubMed ID: 31454290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
    BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies.
    Obianom ON; Okusanya OO; Earp J; Thway TM
    Clin Pharmacol Ther; 2020 Jul; 108(1):107-115. PubMed ID: 31957006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.